A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT04773522 · COMPLETED

Trial details

NCT number: NCT04773522
Sponsor: Janssen Pharmaceutical K.K.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2021-05-20
Primary completion: 2022-10-14
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.